Dendreon shares slump as demand for Provenge disappoints
This article was originally published in Scrip
Executive Summary
Dendreon has been forced to withdraw its sales estimates for 2011, claiming the uptake of its therapeutic prostate cancer vaccine Provenge (sipuleucel-T) is being hampered by confusion over reimbursement. That official company line has been countered by others who say that demand for the treatment per se rather than any confusion is at the root cause of the sale deficit. Dendreon’s share price dived by more than 60% on extended trading on 3 August following the announcement.